GILD · Gilead Sciences, Inc.

Summary

Gilead Sciences held its 2026 annual meeting, electing nine directors and approving executive compensation and the amended 2022 Equity Incentive Plan.

Key takeaways

• All nine director nominees were elected with majority support; Daniel P. O'Day received the lowest 'for' votes at 980.6 million.
• Stockholders ratified Ernst & Young as independent auditor for fiscal 2026 with 1,046.4 million votes for.
• Advisory vote on executive compensation passed with 954.3 million for, indicating shareholder approval.
• Amended 2022 Equity Incentive Plan approved with 970.3 million for, enabling continued equity-based incentives.
• Three shareholder proposals (independent board chair, patent exclusivity report, ESG/DEI metrics report) were all rejected.
• Broker non-votes were significant (95 million) on all director elections and non-routine proposals.